STOCK TITAN

Biohaven - BHVN STOCK NEWS

Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.

Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company pioneering innovative therapies in immunology, neuroscience, and oncology. This page provides real-time access to official press releases, financial disclosures, and progress updates on Biohaven’s cutting-edge platforms like the MoDE protein degradation technology and TRAP degraders.

Investors and industry professionals will find curated updates on clinical trial milestones, regulatory submissions, and strategic partnerships. Key content includes earnings reports, FDA communications, and advancements in autoimmune disease treatments, neurological disorder therapies, and oncology programs.

Bookmark this page for direct access to Biohaven’s verified announcements, ensuring you stay informed about developments impacting the company’s scientific and financial trajectory. Regular updates provide critical insights for evaluating Biohaven’s position in competitive therapeutic markets.

Rhea-AI Summary
Biohaven presents preclinical data on taldefgrobep alfa's ability to reduce fat mass and increase lean mass in obese mouse model
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary
Biohaven closes underwritten public offering, raising approximately $258.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
Biohaven announces pricing of $225 million public offering of common shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
Rhea-AI Summary
Biohaven Ltd. announces a proposed public offering of $200 million of its common shares, with an option for the underwriter to purchase an additional $30 million of shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
-
Rhea-AI Summary
Biohaven completes enrollment in Phase 3 trial for taldefgrobep alfa in spinal muscular atrophy (SMA)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
-
Rhea-AI Summary
Biohaven announces positive biomarker data from Phase 1 EEG study of BHV-7000, confirming CNS activity and dose-dependent effects. Plans to initiate Phase 3 program in focal epilepsy by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
-
Rhea-AI Summary
Biohaven Ltd. announces multiple updates on key programs, including positive preliminary EEG data for BHV-7000, Phase 1 update on BHV-8000, development update on BHV-1300, and regulatory update on troriluzole. BHV-7000 shows promising results in treating epilepsy and bipolar disorder. BHV-8000 achieves projected therapeutic concentrations and is well tolerated. BHV-1300 demonstrates a competitive profile. Troriluzole Phase 3 study enrollment to be completed soon. FDA refuses to review NDA for troriluzole in SCA3, Biohaven requests Type A meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
Biohaven

NYSE:BHVN

BHVN Rankings

BHVN Stock Data

2.08B
86.84M
11.55%
91.82%
8.12%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN